Combining in vitro DNA binding studies and functional transcription assays in the Xenopus oocyte, we have tested the presence and functional state of transcription factors controlling the interleukin-2 (IL-2) promoter through the NFAT binding site. In naive T-helper cells, the IL-2 gene is repressed by a silencer. After first mitogenic stimulation, this silencer becomes undetectable while an activator is newly synthesized. In resting memory cells, the activator has low DNAbinding affinity and is located in the cytoplasm. However, no silencer is formed. Upon renewed cellular activation, this pre-existing activator is again targeted to the nucleus and regains function in promoting transcription. Cyclosporin A HE PRODUCTION O F interleukin-2 (IL-2) is controlled mainly at the transcriptional level' and the cisacting sequences critical for its regulation are located within 320 bp upstream the cap site.' The transcription factors (TFs) that bind to distinct sites of the IL-2 promoter in T cells include the lymphotropic Octamer, AP-1, and NFkB factors, as well as the cyclosporin A (CsAf-and FK506-sensitive factor NFAT-1 .3"9 The binding site of NFAT-1 is a purinerich (Pu) element present twice in the human promoter at positions -130 (proximal) and -276 (distal). It has been reported that an NFAT-I subunit is present constitutively in the cytoplasm of unstimulated T-cell lines and is tissuespecifi~.'~'~~'' Upon cellular stimulation, this factor, recently characterized for a mouse T-cell clone,'" is targeted to the nucleus, where it is reported to interact with a newly synthesized nuclear subunit to form the positive TF NFAT-I .",''' Treatment with the immunosuppressive drugs CsA or FK506 blocks early events in IL-2 transcription." It has been suggested that the drugs bind to cytoplasmic prolyl cis-tmrrs isomerases (CsA to cyclophilin and FK506 to FKBP) and that the resulting complexes may then interact with the phosphatase calcineurin." The activation of calcineurin, in response to a T-cell receptor (TCR)-induced increase in intracellular calcium, is thought to fuel the translocation of the cytosolic NFAT-1 subunit to the nucleus, where it forms complexes with the nuclear subunit that is synthesized in response to TCR-induced protein kinase C activation."-*" According to Flanagan et al,9 the drugs block the nuclear 
targeting of NFAT-1, and recently it was reported that, through binding to calcineurin, the drugs render this phosphatase inactive, thus preventing the (de)phosphorylation of the cytoplasmic subunit of NFAT-I needed for its nuclear translocation."." The NFAT-l nuclear subunit was shown to contain members of the oncogenic protein families offi).s and juri." Interestingly, the members of fos and jun that participate in the NFAT-I multimer formation seem to vary with the cell type. The nuclear NFAT-l subunit in the leukaemia Jurkat was shown to contain c-jun or junD, fos, and, to a lesser extent,,frc-I," whereas in primary human T cells it was shown to contain ajunB-frtl-l heterodimer."
It has also been suggested that in certain cellular activity phases, for instance, when the cells are resting" or are anergic,'" the IL-2 gene may be downregulated by a transcriptional silencer(s). A silencer has been identified that binds to an element ( -110 to -101 ) situated between an Octamer 1 and,fos-jun binding sites in Jurkat and Raji B cells." ' We studied the presence and function of TFs that control IL-2 transcription in primary T cells by DNA-protein binding studies and a functional trans-activation assay in Xenopus oocytes. The latter involves microinjection of a target gene and putative regulatory factors into the oocyte, to assess whether transcription is upregulated or do~nregulated.".'~ The IL-2 promoter, like most injected genes, exhibits a basal activity in oocytes. Addition of proteins extracted from total resting T cells isolated from mouse spleen2'~*' or human peripheral blood"'.'' silences the basal activity of the fulllength (2-kb) IL-2 promoter, independent of whether it is linked to the IL-2 gene including introns and 3' flanking sequences or to a CAT coding sequence. Proteins from resting T cells also silence the basal activity of a minimal promoter controlled by 4 copies of the NFAT element. Proteins from resting T cells and the NFAT probe give a fast-migrating complex in bandshifts, the presence of which is strictly correlated with functional repressor activity in the oocyte system. Proteins from activated primary T cells and the NFAT probe give rise to a slower migrating complex. Such extracts only slightly enhance (about 1.5-fold) basal activity, but activation can clearly be monitored in a situation in which previously silenced genes are fully derepressed by the addition of activator. 'x The basal activities of all other minimal IL-2 promoters
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tested exhibited constitutive expression and were not repressed by the addition of resting T-cell extracts, promoters controlled either by the NFkF3, Octamer, or AP-1 binding sites of the E-2 promoter, as well as the herpes simplex virus thymidine kinase gene or the W40 early promoter. Proteins extracted from mouse kidney, liver, brain, or resting human peripheral blood B cells or monocytes or from the tumor cell lines Jurkat or EL4 had no effect on the basal
activities of all the genes tested.32
In the present report, we studied in more detail the presence and function of the factors binding to the NFAT recognition site in naive and memory T-helper (Th) cell populations during the process of cellular induction, and show that only in naive cells is the activator newly synthesized. We also show that in naive T cells CsA or FK506 stabilize the silencer and prevent derepression of the gene by functional activator, whereas in memory cells, the drugs inhibit the nuclear targeting of the activator as well as modifications needed for its function in promoting IL-2 transcription.
Moreover, we have analyzed the importance of some nucleotides involved in binding of silencer and activator from Th cells, and compared them with the requirement for binding of NFAT-l from Jurkat cells. In this respect, no striking differences exist because all factors recognize the same three G residues within their recognition site. Nevertheless, as judged from cross-linking experiments performed with the silencer, activator, and NFAT-1, each factor seems to consist of different subunits in addition to a common one found in all complexes. Finally, supershift experiments show that the activator contains ffa-2 and junD, whereas the silencer proteins cross-react with none of the antibodies tested.
MATERIALS AND METHODS
Cells and Proteins
Total T cells were isolated by rosetting with sheep red blood cells (SRBC) from peripheral blood mononuclear cells of adult donors or umbilical cord blood, and Th cells were purified by positive selection using immunomagnetic beads (Dynal AS, Oslo, Norway) coated with anti-CD4 monoclonal antibody (MoAb)." Phenotyping for naive or memory cell markers was performed by fluorescence-activated cell sorting (FACS) as described.,' To activate the cells, they were stimulated in cell cultures with 10 ndmL phorbol myristate acetate (PMA) and l pmol/L ionomycine at various times in RPM1 1640 medium with 10% fetal calf serum (FCS) and standard supplements. IL-2-secreting, CD4+/CD45RO+ T-cell clones were derived from peripheral blood T cells as de~cribed.~' The clones were either cultured for 2 weeks in plain culture medium (resting memory cells tested for viability, IL-2 secretion, and mRNA synthesis) or stimulated with PMA and ionomycine. When required, the cells were cultured in the presence of 20 pdmL cycloheximide or 1 pglmL CsA or 20 ng/mL FK506. Jurkat cells were cultured and stimulated with PMA and ionomycin, as were the Th cells.
To produce protein extracts, total cells were lysed, sonicated, and salt adjusted to 300 mmol/L to extract proteins from chromatin, and the lysate was centrifuged at 100,OOOg for 1 hour and the supernatants were dialyzed against KIB buffer (Mouzaki et alz8 and references therein). When indicated, we prepared separate fractions of nuclear and cytoplasmic protein^.^' Proteins were extracted from Jurkat cells using the method', modified in that the cell lysate was centrifuged at 100,OOOg to sediment chromatin and the supernatant was dialyzed against KIB buffer. Protein concentration was determined using the Bradford assay (BioRad, Hercules, CA).
Oligonucleotide Probes
The following oligonucleotide probes we used. Long Pu-probe was used corresponding to the NFAT element and including an etslike element (bold) and a cryptic AP-l site (italic): AAGAAAG-GAGGAAAAACTGZTCATAAGGA. To test the binding patterns of the NFAT-binding factors derived from naive or memory Th cells at different activity phases as well as from Jurkat cells, we used a short Pu probe (AAGAAAGGAGIG2AAAAACTG3T), from which half of the cryptic AP-l site is missing but the third G residue is conserved. In the mutant oligonucleotides G1, G2, and G3, the corresponding G residues G , , G 2 . and G,, respectively, were replaced by a T.
For cross-linking experiments, a long Pu oligonucleotide and a 9mer (capitals) were hybridized and filled in (small letters) with Klenow polymerase in the presence of 100 m m o K dGTP, dCTP, N,-dUTP,'4 and 10 mmol/L of '*Pa-dATP for 30 minutes at room temperature: AAGAAAGGAGGAAAAACTGTTTCATAAGGAa; uucuuuccuccuuuuugacaaaGTATTCCIT.
Electrophoretic Mobility Shift Assays (Bandshifts)
These assays were performed as de~cribed.9~ Briefly, 5 pg of protein (or as stated) was incubated with about 120 pg DNA radiolabeled short Pu probe (l0,OOO to 30,000 cpm) in the presence of 0.5 pg poly(dIdC) nonspecific competitor DNA per microgram of protein in a total reaction volume of 15 /*L. After incubation for 15 minutes at room temperature, the samples were fractionated on 4% or 5% denaturing polyacrylamide gels at 10 V/cm for 1.5 or 2 hours, respectively. In competition experiments, a 50-to 500-fold excess of cold short Pu or G mutant probes was added to the reaction mixture before the addition of the proteins. To compare the binding affinities of factors shown in Fig 3c, Figs 5 and 6 , low exposures were scanned using a computing densitometer and the data analyzed using ImageQuant V3.0 software, both from Molecular Dynamics (Sunnyvale, CA).
UV cross-linking. The binding reactions (in Eppendorf tubes) were irradiated for 20 minutes on ice at a distance of 10 cm, using a UV transilluminator (254 nm, 7000 pW/cm*). Using N3.dUTP, 5% to 15% of total protein-DNA complex is ~ross-linked.'~ Crosslinked material was separated on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels with prestained molecular weight (Mr) markers and visualized by autoradiography.
Supershifl experiments. These experiments were performed by the addition of antibodies (2 pg each) to the bandshift reaction mixtures. The antibodies (Abs) used were rabbit polyclonal IgG (exceptions are noted), all purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). The Abs were specific to their antigen and, with the exception of ets-l, not cross-reactive with other closely related proteins. The Abs were directed against the AP-I transcription factors c-fos p62, fosB, fra-l, fra-2 p46, c-jun p39, junB p39, and junD p39; the NFkB transcription factor subunits p65 and p50; c-ref p75; ets-l p54 (cross-reactive with ets family proteins), and the tumor-suppressor protein p53 (mouse IgG2a).
Xenopus Oocyte Injection and Target Genes
The Pu-CAT gene clone4 used for injections contains four copies of the murine NFAT promoter element in front of a truncated (-81) HSV thymidine kinase promoter and a CAT-coding segment. In
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 2614 addition, we constructed a 3xPuAP-CAT clone with three copies of the corresponding human sequences AAGAAAGGAGGAAAA-ACTGTTTCATAG inserted into the blunted Xba I site upstream of the SP-I motif of PBL~-CAT.~' Orientation of the inserts was tested by cutting with Xba I and Xho 1. Similarly. a 3xPu-CAT clone was constructed in which the cryptic AP-I site was truncated but the G3 residue still present (AAGAAAGGAGGAAAAACTGT). The 3xAP-I-CAT clone contains three copies of a consensus AP-I site: AAGTTATGACTCACCG.'* As a control, pBL2-CAT was used.
Functional assays in the Xenopus oocyte system are described in detail elsewhere (Rungger et al." Mouzaki et al,'x and references therein). Proteins (5 ng per injection per oocyte) were injected into the oocyte cytoplasm (groups of 1. 5 oocytes). Two hours later, when the nuclear proteins had migrated to the germinal vesicle. I ng of DNA was injected intranuclearly, immediately followed by a second cytoplasmic or nuclear injection of proteins as indicated. Eighteen to 20 hours later, the activity of the target genes was measured by CAT assays as described.'* Usually. I O oocytes were lysed, and an aliquot corresponding to 1 oocyte was processed.
RESULTS
NFAT-Binding Factors in Naive Human T Cells
Bandshifts with proteins from resting or stimulated naive T cells isolated from cord blood and the NFAT probe (Fig  1 a, right-hand panel) show that the silencer can be detected until about 6 hours after addition of the mitogens. By about I O hours of mitogenic stimulation, the silencer disappears and the activator complex appears. Although the timing of the appearance of the activator vanes with different batches of cord blood, after performing several independent experiments we have seen that it appears at the earliest after 6 hours of stimulation with PMA and ionomycine; if the cells are stimulated with PMA alone or with phytohemagglutinin (PHA) and PMA, it can take longer than I O hours and as long as 24 hours to detect the activator in bandshifts (data not shown). It appears therefore that a combination of PMA and ionomycine is necessary for the synthesis of the activator from in vitro-stimulated cord blood-derived naive T cells (ie, strong calcium dependency). The activator is formed through de novo protein synthesis because it does not appear when the cells are stimulated in the presence of the translational inhibitor, cycloheximide (or anisomycine; data not shown). On the other hand, the disappearance of the silencer on cellular stimulation is independent of translation. Bandshifts performed with a labeled NFAT element and proteins from resting or stimulated Th cells isolated from adult peripheral blood are shown for comparison in Fig la (left  panel) .
Functional tests were performed in the Xenopus oocyte with the same protein extracts that were used for the bandshift assays (Fig I b) . The results show that proteins extracted from resting naive or total T cells downregulate the basal transcription of a hybrid gene under the control of four NFAT promoter elements (4xPu-CAT). Extracts prepared between 2 to 6 hours after mitogenic stimulation of naive cells also downregulate the gene. hours in which the silencer is still present and the activator has not been synthesized. By contrast, I O hours after stimulation, the activator has been formed, and the resulting protein extracts fully derepress the silenced target promoter. When activator formation is blocked by cycloheximide, no such derepressing activity is obtained. In addition, the repressing activity of proteins from cells stimulated in the presence of cycloheximide is lost along with the disappearance of the silencer complex in the bandshift assay. the activator, see below), whereas the latter fully derepress the gene silenced with proteins from resting or 4-hour activated cord blood cells that were not treated with CsA (lanes 6 and 7, Fig 2a) . Failure of derepression is not caused by drugs transfered along with the protein extracts'" or by some unknown components in the extract from drug-treated cells that would inhibit nuclear migration of the activator' in the oocyte host. Normal activator from stimulated memory cells also fails to derepress the IL-2 promoter, silenced with extracts from drug-treated cells, even if it is added directly to the nucleus (Fig 2b) . Identical results have been obtained with extracts from cells that were treated with FKS06 instead of CsA (data not shown). These observations indicate that the silencer is altered by CsA (or FKS06) so as to become resistant to displacement by activator.
NFAT-Binding Factors in Memo97 Human T Cells
Contrary to naive T cells, memory cells have no silencer." We have thus assessed more precisely the mechanism by which the IL-2 gene is controlled in these cells. Bandshifts with the NFAT probe and proteins extracted from a memory T-cell clone (Fig 3a) show that no trace of silencer-like protein is found, but that protein forming activator-like complexes is present in both resting or stimulated memory cells, independently of whether cycloheximide was added during mitogenic stimulation. Bandshift assays performed with nuclear and cytoplasmic extracts prepared from resting or activated memory cells show that, similar to the situation described for NFAT-I: the activator is located in the cytoplasm of resting cells and is transported to the nucleus in activated cells (Fig 2b) . Concomitant to the nuclear targeting, the activator appears to gain affinity in DNA binding. A titration of factor by increasing amounts of DNA, indicates that DNAbinding of the activator increases at least fourfold during cell activation (Fig 3c) . Because de novo synthesis is not needed for the activator of memory cells to become func- For
, this increase is likely to be caused by an increased DNA-binding affinity. The functional capacity of the activator closely reflects this alteration in affinity (Fig 3d) . Proteins from resting memory cells, although they have no silencing activity on the IL-2 target promoter, are not capable of derepressing genes that were previously silenced with a dose of proteins from resting Th cells purified from adult peripheral blood. Extracts from activated memory cells, on the other hand, fully reactivate silenced genes, independently of whether the donor cells were stimulated in the absence or presence of cycloheximide (Fig 3d) . These observations suggest that, in vivo, once acquired during a first mitogenic stimulation, the activator is maintained. In memory cells, IL-2 regulation now proceeds in the absence of a silencer, through postranslational modifications of the activator that determine its cellular location, DNA-binding affinity, and its function in transcriptional activation of the IL-2 promoter.
Efiect of CsA or FK506 on Actiwtor
The addition of CsA or FKS06 to memory cells at the beginning of their mitogenic stimulation causes effects that closely resemble those described for NFAT-1 ." As verified by bandshifts performed with nuclear and cytoplasmic proteins extracted from memory cells that were activated in the presence of either drug (shown here for CsA), nuclear targeting of the preformed activator is inhibited (Fig 4b) . Proteins from drug-treated memory cells did not affect the basal activity of the Pu-CAT gene in the oocyte (Fig 4e) .
The differences observed between the factors binding to the NFAT recognition site in naive and memory T cells have been shown in this report using naive (cord blood-derived) and memory T cells (clone). We performed an additional series of experiments aiming to directly compare these factors with factors from total T cells isolated from adult peripheral blood that contains a mixture of naive and memory cells (Mouzaki et a13' and references therein). To this end, we isolated cytoplasmic proteins from total resting T cells and then extracted proteins from chromatin of the same cells with salt washes and performed bandshift assays with the NFAT probe. In the same experiment, we also used proteins extracted from stimulated T cells. The resulting bandshifts are shown in Fig 4a and confirm that ( 1 ) in resting cells the silencer is found only in the nucleus and (2) the activator only in the cytoplasm, and that (3) the nuclear and cytoplasmic activator from ex vivo T cells forms complexes of the same size in bandshifts as cytoplasmic or nuclear activator isolated from pure memory CD4' cells. The cytoplasmic form of activator isolated from adult peripheral blood cells does not affect the basal activity of the Pu-CAT gene in the oocyte (Fig 4c) and it is incapable of derepressing silenced genes regardless of whether it is injected into the oocyte nucleus or cytoplasm (Fig 4d) .
Binding Requirements and Subunit Composi~ion of the
Silencw and Activator
The silencer and activator of Th cells and NFAT-I of Jurkat cells all act through the same recognition sequence. To sort out whether differences exist in the residues recog- 
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nized by the different factors, we first narrowed down the sequences required for correct regulation of the IL-2 gene. To this end, we constructed the 3xPuAP-CAT clone with the complete Pu-rich motif and the cryptic AP-I site, the 3xPu-CAT in which the AP-I motif is truncated, and a 3xAP-l-CAT clone with a consensus AP-I motif. These three clones were used for transcription assays in the Xenopus oocyte (data not shown). Both, the human 3xPuAP-CAT and 3xPu-CAT clones are regulated as the original murine 4xPu-CAT clone used above, ie, they are repressed by injection of proteins from resting naive Th cells and derepressed by the later addition of proteins from stimulated T cells. By contrast, the 3xAP-I-CAT, like the pBL2-CAT clone used a control, displays basal activity, but is not regulated by silencer-or activator-containing extracts. Thus, the presence of the complete cryptic AP-I site does not seem to be necessary for correct IL-2 regulation and a canonical AP-I site cannot assume this function alone.
Binding of proteins extracted from stimulated total peripheral blood T cells to the NFAT probe has been shown to involve three G residues," two of which lay within the Purich motif and the third in the cryptic Ap-l site. We tested the importance of these three residues also for the binding of silencer and activator from Th cells. We first tested the binding of a wild-type Pu probe and of the GI, G2. and G3 mutant probes with increasing amounts of silencer from resting cells and from resting and FKS06-treated cells or of cytoplasmic or nuclear activator from memory cells. The raw data for the cytoplasmic activator and the FKS06-treated silencer are shown in Fig 5a. The autoradiograms were scanned and the data from all experiments, normalized to maximal binding of the wild-type Pu probe by the respective protein, are summarized in Fig 5b. The results show that all proteins bind the wild-type Pu probe and about half as efficiently also retard the G3 mutant. By contrast, the GI mutation is hardly recognized by any of the proteins and recognition of the G2 mutant is very weak also.
To evaluate more critically binding affinity, we performed competition experiments with these probes. The same proteins were incubated with hot wild-type Pu probe in the absence or presence of a 50-or 500-fold excess of cold wild-type Pu or mutant GI, G2, or G3 probes. The data, normalized to Pu-binding in the absence of competitor, are shown in Fig 6. In agreement with the above binding studies, the Pu element competes efficiently with its binding and the G3 mutant is capable of competing with the wild-type probe, although only at a high excess. Moreover, it appears that the third G residue is more important for NFAT-I binding than for binding of silencer. Despite such slight variations, there is no decisive difference emerging between the binding properties of the silencer and activator from Th cells and NFAT- major retarded complexes nor any larger complexes indicative of interactions between silencer and activator subunits.
Cross-linking studies are another possibility to test differences between factors binding to the same recognition motif. To perform such experiments, we used Azido-dUTP," which strongly enhances efficiency of UV cross-linking of proteins to DNA. A long Pu probe was produced in which the T residues of the strand complementary to the purine-rich region were replaced by such N3.dUTPs. Analysis of crosslinked complexes on denaturing SDS-PAGE (Fig 7b) shows several bands for each of the Pu-specific factors tested. The silencer, activator, and NFAT-I extracts yield a common complex (open circle) with a size of about 40 kD, including the 30-bp-long cross-linked probe. About 10 kD (single strand) has to be deduced from all values. The common band could be a general DNA-binding protein (in view of its size, probably histone HI). In addition, several complexes of different sizes are formed by each protein preparation (black dots). The silencer forms two more bands (44 and 46 kD), the activator two larger bands (S3 and 62 kD), and NFAT-I a whole array of complexes (43, SO, 58, 67, and 105 to 130 kD). Deducing the probe, the main constituents of the silencer and activator range in size between 30 and S0 kD.
The Th Cell Actiwtor Contcrins fra-2 and junD Supershift experiments were performed with antibodies raised against the AP-I transcription factors c$)s p62, fosB, .fra-l. .fra-2 p46, c-jun p39. jlrnB p39, and junD p39; the NFkB transcription factor subunits p65 and p50; c-re1 p75; ets-l pS4, and the tumor-suppressor protein pS3. They show that the Th cell activator containsfos andjtm proteins, specifically ,fra-2 and jtrnD (for a typical fluorogram see Fig  8a) . The silencer was not supershifted by any of the above antibodies (some of the assays are shown in Fig 8b) .
DISCUSSION
Fundamental changes occur in the mechanism regulating the IL-2 promoter during naive Th cell transition from the resting to the activated state (summarized in Fig 9) . In resting naive Th cells, the IL-2 promoter is negatively regulated by a silencer binding to the NFAT promoter element. Within an average of 8 hours after the first mitogenic stimulation, two concomitant but independent events take place. The silencer disappears and an activator is formed through protein kinase C activation and de novo protein synthesis, and promotes IL-2 transcription by binding to the same element.
Resting memory cells do not synthesize IL-2 but this is not because the silencer reoccupies the NFAT element (Mouzaki et al" and this report). Instead, the activator becomes functionally inactive and is translocated to the cytoplasm. The transcriptional arrest of the IL-2 gene is thus differentially regulated in memory Th cells. When memory cells are restimulated, the activator quickly regains function through posttranslational modifications and is translocated into the nucleus. In this situation, de novo protein synthesis is not necessary to obtain a functional transcriptional activator. Although these features resemble the behavior of NFAT-I in T cell line^,".^'."' in the latter, the cytoplasmic subunit joins a newly synthesized nuclear subunit to form the trcms-active nuclear factor NFAT-1.
The action of immunosuppressive drugs on the memory cell activator resembles closely the mechanism proposed for NFAT-I in Jurkat cells." In both cell types. the nuclear translocation of the preformed positive TF is inhibited. It thus appears that the activator undergoes modifications similar to those described for NFAT-I, ie, dephosphorylation by calcineurin that is prevented by the CsA-cyclophilin comPlex."-?" 
NUCLEAR SUBUNIT SYNTHESIS
The activator is not the only target of CsA action. When resting naive cells are cultured with CsA or FK506, or if either drug is present during their mitogenic stimulation, the silencer seems to be altered as well. Such protein extracts exhibit a repression that, contrary to that caused by normal silencer (extracted from resting, untreated naive cells), cannot be overcome by activator injected into the oocyte. Evidence that CsA treatment has a direct effect on silencer stability and does not merely inhibit nuclear transport of injected activator is provided by three observations. ( I ) Direct injection of drugs into the oocyte has no effect on the activity of silencer or a~tivator.'~ (2) Nuclear injection of the activator also fails to derepress the IL-2 promoter (this report). (3) Irreversible silencing is also obtained with proteins extracted from cells cultured with CsA without being exposed to mitogenic stimulation (this report).
Thus, the maintenance of a given phosphorylated or dephosphorylated state of the silencer protein would in this case have to be a continuous process. Because this process is affected by CsA and FKS06, it may depend on calcineurin action as well.
An important question concerns the relationship between silencer and activator on one side, and activator and NFATl derived from tumor cell lines, such as the leukaemia Jurkat, on the other. As far as the contacted residues within the recognition sequence are concerned, no striking differences could be observed. The silencer and activator both bind less efficiently to mutant oligodesoxynucleotides in which any of the three G residues contacted by a protein from stimulated peripheral blood T cells" was substituted by a T residue. Moreover, no apparent difference exists in this respect in the binding pattern between normal silencer and silencer from FK506-treated cells, nor between inactive cytoplasmic and functional nuclear activator. If ever, the third G residue located in the noncanonical AP-l site seems less important for silencer binding than for binding of activator and NFAT- However, marked differences exist in the subunit composition of the silencer and activator. The cross-linking studies show that each factor contains two subunits that clearly differ in size. Whether the common band corresponds to a common subunit or is due to cross-linking of general DNA-binding proteins (probably histone HI) present in the incubation mixture cannot be decided yet. The presence of two bands may be due to the cross-linking of one or the other constituents of a heterodimer. Cross-linking of both components would be less efficient and could not be detected. The presence of one slightly larger band in the activator analysis, as judged from its size, may rather be due to an additional single component than to a dimer. Although in the presence of the cross-linked probe, molecular weight is difficult to estimate, the apparent size of these subunits lies between 30 and SO kD and is compatible with the identification of some subunits (see below).
Moreover, the different subunits of the two factors seem not able to form hybrid complexes when the respective protein extracts are mixed. This might be due to the fact that each factor always exists as dimer or multimer, and that no free subunits are available that could form such hybrids. However, we assume, that the subunits of the different TFs are entirely different and are not capable of interacting with each other.
Additional evidence that the constituents of the silencer and activator are different has been obtained by supershift experiments. The activator contains fru-2 and junD (rather thanfru-1 and junB).'* By contrast, the silencer still escapes identification. None of the numerous antibodies directed For personal use only. on September 24, 2017. by guest www.bloodjournal.org From against known TFs were capable of supershifting the silencer complex. The main silencer components are thus different from those of the activator. Purification and molecular characterization of the silencer is underway and will clarify this question.
The behavior of memory T-helper cell activator resembles in its nuclear-cytoplasmic shuttle, and also in its response to immunosuppressive drugs, the well-characterized behavior of NFAT-l from tumor cell lines (see introduction for references). Also, the subunit composition of the activator, including fru-2 and junD, as determined by our supershift experiments, is similar to that of the Jurkat NFAT-1, the AP-I component of which was reported to include junD, cjun, or fos." However, in our cross-linking gels, NFAT-1 contains many components and some large proteins are involved as could be expected from data published by others.~7.~9,2n We had no antibody to test for the presence of the 120 kD component corresponding to NFATp,'" but, in the cross-linking experiment, the activator yields a relatively weak signal corresponding to a protein of this size.
An important difference between NFAT-l and activator resides in the fact that formation of activator in memory cells is independent of de novo protein synthesis (this report), whereas a nuclear subunit of NFAT-l has to be newly synthesized upon Jurkat cell activation.',' In addition, the two complexes are functionally different in that NFAT-l is not capable of derepressing silenced IL-2 promoters, as we have shown earlier." Differences appear also in bandshift experiments on the level of nondenatured complexes. In general, NFAT-l (isolated from two batches of Jurkat cells using the same method we use to extract activator from ex vivo T cells) shows larger c~mplexes.'~ Such differences may not be too surprising, because NFAT-like elements are found in the promoters of many cytokine and viral genes and proteins binding to such motifs can be derived from different cell types such as T cells, B cells, monocytes, mast cells, and NK cell^.^^^')^^' The resulting protein complexes seem to have a common component, NFATp, which, like the memory cell activator, may act alone4' or in conjunction with several other proteins that vary depending on the promoter and cell type." In addition, the distal NFAT element of the IL-2 promoter was shown to form identical complexes in vitro when incubated with protein extracts from T or B cells, but, upon transfection, the NFATd element was inactive in B cells.42 It thus seems that NFAT-I is a collective term for a variety of NFATbinding multimers.
Conclusively, IL-2 regulation is different in Th cells and in tumor cell lines. The main differences reside in the existence of an IL-2-specific repressor in resting naive Th cells that is not found in other lymphoid cells, primary or immortalized. As far as the activator is concerned, it is formed through de novo protein synthesis only during first mitogenic stimulation of naive Th cells, whereas later on its activation and deactivation depends on posttranslational modifications, and no subunit has to be formed each time through de novo protein synthesis. Moreover, the effect of immunosuppressive drugs is not identical in different types of T cells either. Whereas the effect on the Th cell activator and NFAT-I is similar and consists in blocking of modifications of the preexisting cytoplasmic activator or NFATp, in naive Th cells the drugs also affect the functional state of the silencer that becomes resistant to displacement. These observations may be pertinent for our understanding of 1L-2 gene regulation and evaluating drug effects in vivo.
